Core Viewpoint - XOMA Royalty Corporation has successfully sold its remaining Kinnate pipeline assets for up to $270 million in upfront and milestone payments, along with royalties on future commercial sales [1][2] Group 1: Financial Details - The total potential financial benefit from the sale includes up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens [1] - Holders of Kinnate Contingent Value Rights (CVRs) will receive 85% of all related payments made to XOMA Royalty prior to April 2, 2029 [2] Group 2: Company Background - XOMA Royalty Corporation operates as a biotechnology royalty aggregator, acquiring future economic rights associated with therapeutic candidates licensed to pharmaceutical or biotechnology companies [3] - The company provides non-dilutive, non-recourse funding to sellers, enabling them to advance their internal drug candidates or for general corporate purposes [3] Group 3: Current Portfolio - As of the date of the press release, XOMA Royalty's milestone and royalty portfolio includes commercial assets such as VABYSMO®, OJEMDA™, MIPLYFFA™, XACIATO™, IXINITY®, and DSUVIA® [6]

XOMA Corporation (XOMA) FY 2025 Conference February 11, 2025 03:20 PM ET Company Participants Owen Hughes - CEOBrad Sitko - Chief Investment Officer Conference Call Participants Trevor Allred - Biotech Analyst Trevor Allred Morning, everyone or good afternoon, everyone. I'm, Trevor Allred, one of the biotech analysts here at Oppenheimer. We have with us today, CEO, CEO Owen Hughes and Brad Sitko, CIO from Zoma Royalty, here with us to disc discuss the company. So let's kick things off. So, you know, you're ...